Genomic Health (GHDX) Tops Q1 EPS by 6c

Genomic Health (NASDAQ: GHDX) reported Q1 EPS of $0.34, $0.06 better than the analyst estimate of $0.28. Revenue for the quarter came in at $108.8 million versus the consensus estimate of $106.68 million.

• "We expect to achieve double-digit revenue growth for the year with continued growth across key products and look forward to the national reimbursement decision in Germany for the Oncotype DX breast cancer test."

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c